FDA Approves Subcutaneous Vyvgart Hytrulo for Generalized Myasthenia Gravis
TUESDAY, June 27, 2023 (HealthDay News) — The U.S. Food and Drug Administration has approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) subcutaneous injections for the treatment of generalized myasthenia gravis (gMG) in adult patients…
Learn MoreFDA Approves Litfulo for Teens, Adults With Alopecia Areata
TUESDAY, June 27, 2023 (HealthDay News) — The U.S. Food and Drug Administration has approved Litfulo (ritlecitinib) for adults and adolescents aged 12 years and older with severe alopecia areata at a recommended dose of 50 mg. Approval of Litfulo was…
Learn MoreADA: Once-Weekly Tirzepatide Leads to Weight Loss in Patients With Obesity, T2D
TUESDAY, June 27, 2023 (HealthDay News) — Once-weekly tirzepatide provides substantial and clinically meaningful reductions in body weight in adults with obesity and type 2 diabetes, according to a study published online June 26 in the The Lancet to …
Learn MoreADA: Once-Daily Semaglutide Superior for Reduction in Body Weight
TUESDAY, June 27, 2023 (HealthDay News) — Oral semaglutide 50 mg once daily leads to a superior and clinically meaningful reduction in body weight for adults with overweight or obesity without type 2 diabetes, according to a study published online Ju…
Learn MoreAdaptation to Pharmacotherapy Does Not Up Smoking Cessation in Black Adults
TUESDAY, June 27, 2023 (HealthDay News) — For Black adults who smoke, adaptation to varenicline and/or bupropion plus nicotine patch (NP) does not improve abstinence rates compared with NP monotherapy, according to a study published online June 20 in…
Learn MoreNew Competitor to Wegovy Shows Promise in Clinical Trials
TUESDAY, June 27, 2023 (HealthDay News) — An experimental drug appears to outperform the trendy medications Wegovy and Ozempic for both weight loss and diabetes control, a pair of early clinical trials shows.Retatrutide helped people with obesity dro…
Learn MoreADA: Bempedoic Acid Cuts MACE in Statin-Intolerant Patients
MONDAY, June 26, 2023 (HealthDay News) — Bempedoic acid is associated with a reduction in major adverse cardiovascular events among statin-intolerant primary prevention patients, according to a study published online June 24 in the Journal of the Ame…
Learn MoreADA: Once-Daily Orforglipron Linked to Significant Weight Reduction
MONDAY, June 26, 2023 (HealthDay News) — The nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron as a once-daily oral therapy is associated with clinically significant weight reduction, according to a study published online June …
Learn MoreTreatment-Resistant High Blood Pressure May Be More Common Than Thought
MONDAY, June 26, 2023 (HealthDay News) — One in 10 people with high blood pressure suffer from a treatment-resistant type of hypertension, yet these patients aren’t always getting the right medication, a new study finds.”Apparent resistant hypertensi…
Learn MoreSecond-Line Switch to Dolutegravir Noninferior in HIV
FRIDAY, June 23, 2023 (HealthDay News) — For patients with HIV without genotype information, a second-line switch to dolutegravir is noninferior to a regimen containing a ritonavir-boosted protease inhibitor (PI), according to a study published in th…
Learn More